ARTICLE | Company News
Court of Appeals denies Acorda's injunction for Ampyra
July 27, 2018 6:27 PM UTC
Acorda Therapeutics Inc. (NASDAQ:ACOR) said the U.S. Court of Appeals for the Federal Circuit denied the company's injunction to prevent generic competition for Ampyra dalfampridine from entering the market while an appeal of a district court ruling is ongoing.
In 2017, the U.S. District Court for the District of Delaware ruled that four of five patents covering the multiple sclerosis drug were invalid on grounds of obviousness. The remaining patent, U.S. Patent No. 5,540,938, was deemed valid but expires in July...
BCIQ Company Profiles